We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

19 May 2026 - 22 May 2026
17 Jun 2026 - 19 Jun 2026
05 Oct 2026 - 06 Oct 2026

First-Of-Its-Kind Drug Illuminates Nerve Tissue for Faster and Safer Surgery

By HospiMedica International staff writers
Posted on 07 Jul 2025

Surgeons face significant challenges when performing procedures near nerves, as they must work cautiously to avoid causing nerve damage, which can complicate the patient's recovery. More...

Electrophysical monitors and anatomical knowledge are essential in identifying and protecting nerves, but they often lack the precision needed for safe, efficient surgery. The lack of clear visibility of nerves, especially during delicate surgeries, can increase the risk of injury. Now, a first-of-its-kind drug that binds to nerve tissue and fluoresces enables surgeons to see the nerves more clearly, thus improving the odds of safer surgery.

This breakthrough drug, developed at the University of New Mexico (Albuquerque, NM, USA) in collaboration with other institutions and known as bevonescein, is a short chain of amino acids attached to a fluorescing molecule. It was created to enhance visibility during surgeries by making nerve tissue more visible to surgeons. The drug is infused intravenously before surgery and binds to nerve tissue, making it visible under specific light conditions in the operating room, where it fluoresces as yellowish-green structures that thread through the surrounding tissue. In a clinical trial involving 27 cancer patients, bevonescein was tested to evaluate its safety and efficacy during surgeries such as neck dissection, parotid surgery, and thyroid surgery.

The results of the small Phase 1-2 study, published in Nature Communications, showed that bevonescein successfully highlighted nerve tissue during surgery, significantly improving the chances of avoiding nerve injury. A larger Phase 3 study is currently underway to assess whether use of the imaging agent meaningfully improves overall surgical outcomes. If successful, bevonescein could gain FDA approval and be used in a wide range of surgical procedures, not just in head and neck surgeries. Researchers are also exploring the use of magnifying loupes, a more portable option for surgeons, to test bevonescein in real-world settings.

“The way that I explain this drug to patients is that I think if we can help surgeons see things better, they can do faster, more efficient, safer surgery,” said Ryan Orosco, MD, UNM.

Related Links:
University of New Mexico


New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Gold Member
12-Channel ECG
CM1200B
New
Glucose Meter
StatStrip®
New
Gas Analyzer
GE SAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: In a new clinical study, the Camstent Coated Catheter was shown to reduce CAUTIs and antibiotic use compared with standard care (photo courtesy of Camstent)

Bacteria-Resistant Urinary Catheter Coating Reduces Infections and Antibiotic Use

Catheter-associated urinary tract infections (CAUTIs) are a major hospital-acquired infection, responsible for about 75% of urinary tract infections acquired in hospitals. They increase morbidity and drive... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.